ERBB2 and triple-negative breast carcinoma: Triple-negative breast cancer, immunohistochemically defined by lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), is an important phenotype of breast cancer that accounts for approximately 10–15% of all breast cancers [1]–[3].